A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

Background: Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve tumor control paralleled by modes...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Heudobler, Daniel, Schulz, Christian, Fischer, Jürgen R., Staib, Peter, Wehler, Thomas, Südhoff, Thomas, Schichtl, Thomas, Wilke, Jochen, Hahn, Joachim, Lüke, Florian, Vogelhuber, Martin, Klobuch, Sebastian, Pukrop, Tobias, Herr, Wolfgang, Held, Swantje, Beckers, Kristine, Bouche, Gauthier, Reichle, Albrecht
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8007965/
https://ncbi.nlm.nih.gov/pubmed/33796020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.599598
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados